P2, N=3, Completed, German Cancer Research Center | Active, not recruiting --> Completed | N=60 --> 3 | Trial completion date: Dec 2024 --> Oct 2023 | Trial primary completion date: Dec 2024 --> Oct 2023

9 months ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Metastases

NRG1 (Neuregulin 1)

NRG1 fusion • NRG1 rearrangement • NRG1 fusion

Gilotrif (afatinib)

12ms

Fluorescent in situ hybridization has limitations in screening NRG1 gene rearrangements. (PubMed, Diagn Pathol)

Considering the high cost of NGS, FISH remains a useful method for screening NRG1 fusions in various types of tumors. This study provides valuable insights into the molecular mechanisms of NRG1 fusion and identifies potential treatment targets for patients suffering from this disease.

12 months ago

Journal

ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NRG1 (Neuregulin 1)

ERBB3 expression • NRG1 fusion • ERBB3 positive • NRG1 rearrangement • NRG1 fusion

over2years

Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements. (PubMed, Cancer Discov)

A patient with CD74-NRG1-positive non-small cell lung cancer who had progressed on six prior lines of systemic therapy, including afatinib, responded rapidly to treatment with a partial response. A CD74-NRG1-positive NSCLC patient who had progressed on six prior lines of systemic therapy including afatinib responded rapidly to treatment with a partial response. Targeting HER2 and HER3 simultaneously with Zeno is a novel therapeutic paradigm for patients with NRG1 fusion-positive cancers.

over 2 years ago

Journal

NRG1 (Neuregulin 1) • CD74 (CD74 Molecule) • ATP1B1 (ATPase Na+/K+ transporting subunit beta 1)

NRG1 fusion • NRG1 rearrangement • NRG1 fusion

Gilotrif (afatinib) • Bizengri (zenocutuzumab-zbco)